Last reviewed · How we verify

Carac® (Fluorouracil) Cream

Actavis Inc. · Phase 3 active Small molecule

Carac® (Fluorouracil) Cream is a Antimetabolite; Pyrimidine analog Small molecule drug developed by Actavis Inc.. It is currently in Phase 3 development for Actinic keratosis (topical cream formulation), Superficial basal cell carcinoma (topical). Also known as: 5-FU.

Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase and gets incorporated into DNA and RNA, disrupting nucleotide synthesis and causing cell death in rapidly dividing cells.

Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase and gets incorporated into DNA and RNA, disrupting nucleotide synthesis and causing cell death in rapidly dividing cells. Used for Actinic keratosis (topical cream formulation), Superficial basal cell carcinoma (topical).

At a glance

Generic nameCarac® (Fluorouracil) Cream
Also known as5-FU
SponsorActavis Inc.
Drug classAntimetabolite; Pyrimidine analog
TargetThymidylate synthase; DNA and RNA synthesis
ModalitySmall molecule
Therapeutic areaOncology; Dermatology
PhasePhase 3

Mechanism of action

Fluorouracil (5-FU) is a prodrug that is converted intracellularly to active metabolites (FdUMP and FdUTP). FdUMP inhibits thymidylate synthase, blocking dTMP synthesis and DNA replication. The active metabolites also incorporate into RNA, disrupting protein synthesis. This mechanism preferentially affects rapidly dividing cells, including cancer cells and hyperproliferative skin cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Carac® (Fluorouracil) Cream

What is Carac® (Fluorouracil) Cream?

Carac® (Fluorouracil) Cream is a Antimetabolite; Pyrimidine analog drug developed by Actavis Inc., indicated for Actinic keratosis (topical cream formulation), Superficial basal cell carcinoma (topical).

How does Carac® (Fluorouracil) Cream work?

Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase and gets incorporated into DNA and RNA, disrupting nucleotide synthesis and causing cell death in rapidly dividing cells.

What is Carac® (Fluorouracil) Cream used for?

Carac® (Fluorouracil) Cream is indicated for Actinic keratosis (topical cream formulation), Superficial basal cell carcinoma (topical).

Who makes Carac® (Fluorouracil) Cream?

Carac® (Fluorouracil) Cream is developed by Actavis Inc. (see full Actavis Inc. pipeline at /company/actavis-inc).

Is Carac® (Fluorouracil) Cream also known as anything else?

Carac® (Fluorouracil) Cream is also known as 5-FU.

What drug class is Carac® (Fluorouracil) Cream in?

Carac® (Fluorouracil) Cream belongs to the Antimetabolite; Pyrimidine analog class. See all Antimetabolite; Pyrimidine analog drugs at /class/antimetabolite-pyrimidine-analog.

What development phase is Carac® (Fluorouracil) Cream in?

Carac® (Fluorouracil) Cream is in Phase 3.

What are the side effects of Carac® (Fluorouracil) Cream?

Common side effects of Carac® (Fluorouracil) Cream include Local skin irritation (erythema, burning, pain), Erosion or ulceration at application site, Photosensitivity, Allergic contact dermatitis, Hyperpigmentation or hypopigmentation.

What does Carac® (Fluorouracil) Cream target?

Carac® (Fluorouracil) Cream targets Thymidylate synthase; DNA and RNA synthesis and is a Antimetabolite; Pyrimidine analog.

Related